Abstract:The lipid kinases that generate the lipid signalling phosphoinositides have been established as fundamental signalling enzymes that control numerous aspects of how cells respond to their extracellular environment. In addition, they play critical roles in regulating membrane trafficking and lipid transport within the cell. The class I phosphoinositide kinases which generate the critical lipid signal PIP3 are hyperactivated in numerous human pathologies including cancer, overgrowth syndromes, and primary immunodeficiencies. The type III phosphatidylinositol 4-kinase beta isoform (PI4KB), which are evolutionarily similar to the class I PI3Ks, have been found to be essential host factors mediating the replication of numerous devastating pathogenic viruses. Finally, targeting the parasite variant of PI4KB has been established as one of the most promising strategies for the development of anti-malarial and anti-cryptosporidium strategies. Therefore, the development of targeted isoform selective inhibitors for these enzymes are of paramount importance. The first generation of PI3K inhibitors have recently been clinically approved for a number of different cancers, highlighting their therapeutic value. This review will examine the history of the class I PI3Ks, and the type III PI4Ks, their relevance to human disease, and the structural basis for their regulation and inhibition by potent and selective inhibitors.

Research progress of phosphatidylinositol 4-kinase and its inhibitors in inflammatory diseases

Research Progress of Phosphodiesterase Inhibitors in Inflammatory Bowel Disease Treatment.

Development of small-molecule inhibitors that target PI3K13

Progress in PDE4 Targeted Therapy for Inflammatory Diseases

Development of small-molecule inhibitors that target PI3Kβ

Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections

Phosphodiesterase-4(PDE4) As a Target for Anti-Inflammatory Drug Discovery: Present and Prospect

Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-Kinase.

Advances in Subunits of PI3K Class I in Cancer.

Small Molecules Targeting Phosphoinositide 3-Kinases

Research Advances on Selective Phosphatidylinositol 3 Kinase Δ (pi3kδ) Inhibitors

PI3K Inhibitors for Cancer Therapy: What Has Been Achieved So Far?

Beyond PI3Ks: targeting phosphoinositide kinases in disease

Recent Discovery of Phosphoinositide 3-Kinase Γ Inhibitors for the Treatment of Immune Diseases and Cancers.

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Understanding the Selectivity of Inhibitors Toward PI4KIIIα and PI4KIIIβ Based Molecular Modeling

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics

The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

PI3K: a potential therapeutic target for cancer.

Phosphatidylinositol 3-kinase signaling pathway and inflammatory bowel disease: Current status and future prospects

Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents